Post-Market Surveillance

Why post-market surveillance is a priority for the MHRA AI Airlock programme

Posted by: , Posted on: - Categories: AI Airlock, Post-Market Surveillance

It is widely recognised that AI technologies have the potential to positively transform healthcare by improving patient outcomes, supporting clinical decision-making and helping health services work more efficiently. However, AI systems can behave differently once they move from controlled testing …

2025 in MedTech: a year of innovation, global leadership and regulatory milestones

Rob Reid, MHRA deputy director of innovation devices, at AI Airlock Connect, October 2025 As the end of 2025 rapidly approaches, I find myself searching out those articles and lists that reflect on key moments across the year. Whether it …

MHRA MedTech Regs blog: working together to advance safety, access and innovation

In our September MedTech regulations blog, MHRA Head of Diagnostics and General Medical Devices Joseph Burt seeks stakeholder feedback to two surveys and looks ahead to Autumn updates about the Pre-market statutory instrument, an IVD roadmap and the next IMDRF …